Highly mutated monoclonal antibody 3F2 targets a conformational and strain-restricted epitope in human immunodeficiency virus gp41 with significant antibody-dependent cell cytotoxicity

Devin DeCotes1 · Sarah Baron1 · Jonathon Hoffman1 · Meghan Garrett2 · Hakimuddin Sojar1 · Mark D. Hicar1

Received: 2 January 2022 / Accepted: 17 May 2022 / Published online: 24 July 2022
© The Author(s), under exclusive licence to Springer-Verlag GmbH Austria, part of Springer Nature 2022

Abstract

Identifying epitope targets by studying the native antibody (Ab) response can identify potential novel vaccine constructs. Studies suggest that long-term non-progressor (LTNP) subjects have inherent immune mechanisms that help to control viremia and disease progression. To explore a role for antibodies (Abs) in LTNP progression, our lab has previously characterized a number of highly mutated Abs that target conformational epitopes of the human immunodeficiency virus (HIV) envelope protein from a single LTNP subject (10076). One Ab clone, 10076-Q3-2C6, had significant cross-clade Ab-dependent cell cytotoxicity. To assess if other LTNP subjects produced similar Abs, we expressed another highly mutated Ab from another subject; subject 10002, clone 10002-Q1-3F2 (variable heavy chain, 63.2% amino acid sequence identity to predicted germline). After expression with its native light chain, the recombinant Ab 3F2 bound to the trimeric envelope protein of HIV (trimer), as well as to the ectodomain of gp41. 3F2 binding to gp41 peptide libraries was consistent with non-linear epitope binding and showed possible overlap with the epitope of 2C6. Ab competition assays suggested that 3F2 may bind near the immunodominant epitope 1 loop region (ID1) of gp41. 2C6 blocked the binding of ID1-loop-binding Abs and 3F2 to the trimer, but 3F2 failed to block 2C6 binding. Together, these results suggest that 3F2 binds to a non-linear conformational epitope primarily localized between the epitope of 2C6 and the ID1. Since they are targeted by functional Abs, a more complete understanding of these ID1 and near-ID1 epitopes may be exploited in future immunization strategies.

Abbreviations

ADCC  Antibody-dependent cell cytotoxicity
Abs  Antibodies
ID1  Immunodominant 1 epitope
LTNP s  Long-term non-progressors
nnAbs  Non-neutralizing Abs

Introduction

HIV vaccine development continues to be a daunting task [1]. To elucidate a role in disease progression, we have studied Abs cloned from long-term non-progressors (LTNP s). A number of these Abs target conformational epitopes in gp41 [2]. The recombinant Ab 10076-Q3-2C6 (referred herein as 2C6) is a highly mutated Ab (86% nucleotide sequence identity to germline variable heavy chain 1-69) cloned from an LTNP subject, 10076, with significant viremia at the time of blood sampling (~21,000 copies/mL) [2, 3]. 2C6 is particularly interesting, as it has cross-clade Ab-dependent cell cytotoxicity (ADCC) and can recognize SOSIP protein constructs and protein constructs from all major clades. Structural mapping of the amino acids that are targeted by 2C6 has suggested that 2C6 recognizes a pocket formed by two adjacent gp41 protomers in the intact HIV trimer [4].

Although most vaccine efforts have concentrated on developing broadly neutralizing Abs, neutralization is not the only useful function of anti-HIV Abs. ADCC is of particular interest, as this activity correlated with the protection seen in a recent RV144 vaccine trial [5–7]. Non-neutralizing
Abs (nnAbs) targeting conformational epitopes in gp41 with significant ADCC function are able to limit cell-to-cell spread of infection [8]. nnAbs that target the immunodominant 1 epitope (ID1) of gp41, such as F240 [9] and 7B2 [10], showed gavage protection in macaques against vaginal challenge with simian-human immunodeficiency virus (SHIV) and had an effect on the viral set point [11]. Mutation of the Fc receptor, on which ADCC depends, reduced the protective effect of the neutralizing Ab B12 in a macaque SHIV challenge model [12]. These data suggest that ADCC is a desirable activity to target for vaccination strategies. Improved understanding of the epitope specificity of ADCC Abs is essential for developing effective immunization strategies that optimize protection by these Abs.

As the target of 2C6 in the major clades of HIV is known and it has robust ADCC activity, further identification and analysis of Abs similar to 2C6 should be considered for vaccine development. We originally sequenced other Abs (seven heavy chains with paired light chains) from LTNP subject 10002, whose samples were collected decades after the year of infection and who consistently maintained low to unmeasurable viral loads (65 at the time of blood draw). Two of these Abs (10002-Q1-1H5 and 10002-Q1-3F2, herein referred to as 1H5 and 3F2) formed a clonal group, utilized VH 1-69 (Fig. 1), and were highly mutated. As these utilized the same heavy chain and were even more highly mutated than 2C6, we pursued recombinant expression and functional characterization of the native heavy and light chains from 3F2 to further our studies on highly mutated Abs from LTNP in hopes of increasing our knowledge about the epitope of 2C6.

Materials and methods

Full-length antibody expression and antibody purification

Expression in Free Style 293-F cells (Thermo Fisher Scientific, R79007) and IgG purification utilizing a HiTrap Protein G column (GE Healthcare, 17-0404-01) on an AKTA FPLC System (GE Healthcare, Piscataway NJ) were done as described previously [4].

Direct-binding ELISA

For His-tagged SOSIP ELISA, SOSIP trimmer creation was characterized previously in the respective references (version four (Zm197m v4.1, AMO008 v4.2, and B41 v4.2; [13]) and version five (BG505 v5.2; [14]). ELISA was performed using Ni-NTA plates from QIAGEN Inc. TRIS-buffered saline (TBS) buffer base, blocking with 2% milk, peroxidase-labeled secondary Ab, and 1-step Ultra-TMB (Thermo Fisher Scientific) substrate color development, as described previously [4]. Other direct protein ELISAs used Immulon 2-HB plates, sodium bicarbonate buffer, phosphate-buffered saline (PBS) buffer base, blocking with fetal bovine serum (FBS), peroxidase-labeled secondary Ab, and 1-step ultra-TMB (Thermo Fisher Scientific) color development as described previously [4].

Competition ELISA

ELISA plates were coated with 10 ng of the selected antigen per well in a 0.2 M bicarbonate buffer solution, pH 9.4, and allowed to incubate overnight at 4°C. The next day, the protein coating solution was removed and blocking with 200 µl of 10% FBS in PBS was carried out at 4°C for 2 h. After removing the blocking buffer, 100 µl of the respective Ab diluted in ELISA wash buffer (7.5% FBS in phosphate-buffered saline with Tween 20 [PBST]) was added and allowed to incubate at 37°C for 1 h. The antibody solution was then removed, and the ELISA plates were washed three times with ELISA wash buffer. Biotinylated Abs (performed as described previously [2]) diluted in 7.5% FBS in ELISA wash buffer were then added at 200 ng/well and allowed to incubate at 37°C for 1 h. The biotinylated Abs were then removed, and the plates were washed three times with ELISA wash buffer. Then, 100 µl of streptavidin-horseradish peroxidase (HRP) secondary Ab diluted 1:2000 in 7.5% FBS in ELISA wash buffer was added to the plates and allowed to incubate at 37°C for 1 h. After washing, plates were developed as described previously using 1-step ultra-TMB (Thermo Fisher Scientific) [4].
Proteins were separated by native and non-native SDS-PAGE using a Bio-Rad Mini-Format 1-D Electrophoresis System (Bio-Rad Mini Protein gel, catalog no. 456-1094) using alkaline-phosphatase-conjugated goat-anti-human Ig (Southern Biotech, Birmingham, AL, catalog no. 2010-04) and then NBT/BCIP color developer (Thermo Fisher Scientific, catalog no. 34042) solution as described previously [4].

Antibody-dependent cellular cytotoxicity assay

A rapid and fluorometric ADCC (RFADCC) assay was performed as described previously [4]. The monoclonal Ab F16V3 influenza Ab was included as a negative control, and HIVIG was included as a positive control (both used at 500 ng/µL). For our analysis, we set the percent killing observed with HIVIG to 100% and normalized the rest of the samples to HIVIG. Relative ADCC activity was calculated by dividing the percent activity at that dilution minus background. The data were plotted with the relative ADCC activity on the y-axis and the Ab concentration on the x-axis. The 50% effective concentration (EC50) was determined by fitting a sigmoidal dose-response curve to the data and identifying the concentration needed for 50% ADCC activity.

Peptide-binding ELISA

The following peptides were obtained from the NIH AIDS Reagents Program (ARP): Peptide Array, Human Immunodeficiency Virus Type 1 Potential T-Cell Epitopes (PTE) Env Region, ARP-11551, Group M consensus Env peptides, ARP-9487, Clade B group M Env peptides, ARP-6451, Clade A BG505 Env peptides, and ARP-13123. ELISA plates were coated with 10 µg of the respective peptide per well in 0.2 M bicarbonate buffer, pH 9.4, and allowed to incubate overnight at 4°C. The next day, plates were blocked with 10% FBS in PBS for 2 h at 4°C. After removing the blocking buffer, 100 µl of the respective Ab diluted to 1000 ng/mL in ELISA wash buffer (7.5% FBS in PBST) was added to each well and allowed to incubate at 37°C for 1 h. After 1 h, plates were washed three times with ELISA wash buffer. After washing, the plates were developed as described previously using 1-Step Ultra TMB solution (Thermo Fisher Scientific) [4].

Results

2C6 is a highly mutated Ab with 86.0% nucleotide sequence identity to the predicted variable heavy chain (VH1-69) germline and 81.6% nucleotide sequence identity to the predicted J heavy chain region (JH6) germline. The V gene prediction is kappa 1-39 with 95.3% predicted nucleotide sequence identity to the germline. The amino acid length of 2C6 HCDR3 is 21, and that of KCDR3 is 9. Similar mutations were seen in its clonal relative, 6B8 [2, 3]. From the heavy chains cloned from subject 10002, two sequences (1H5 and 3F2) formed a clonal group and were highly mutated. These are shown in comparison to 2C6 and 6B8 in Figure 1. 3F2 has 79.6% nucleotide sequence identity in the variable chain (VH1-69) and 65.8% identity in the J region (JH6) to the predicted germline. The V gene prediction is lambda 3-25 with 94.4% nucleotide sequence identity to the predicted germline. The amino acid length of 3F2 HCDR3 is 16, and that of LCDR3 is 11. 1H5 has similar mutations and a similar overall structure. These nucleotide changes lead to highly mutated Abs when compared to the germline with amino acid sequence identity to the predicted germline of 77.0%, 75.9%, 67.8%, and 63.2% for 2C6, 6B8, 1H5, and 3F2, respectively (Fig. 1). Both 3F2 and 1H5 have additional structural divergence, with a predicted insertion of a glycine (G) and a serine (S) at variable site 86 (IMGT numbering [15]). There were rare convergent amino acid changes from germline between these antibodies from the two individuals, with two lysine (K)-to-arginine (R) changes (at positions 20 and 70 according to IMGT numbering), which are both positively charged amino acids and likely to be of minimal overall significance.

After its expression as a recombinant antibody, we characterized the binding of 3F2 to a variety of HIV constructs. Our ELISA assays showed that 3F2 readily binds to both trimer and gp41 proteins, although with less efficiency than 2C6 (Fig. 2A and B). As 2C6 could recognize constructs from multiple clades [4], we also assessed 3F2 for possible multiclade recognition of various gp140 trimer constructs (Fig. 2C, open symbols). Compared to published data on 2C6, 3F2 is more restrictive, recognizing only clade B constructs (Bal trimer and JRFL gp140 protein). We next investigated whether 3F2 would bind to the BG505 SOSIP.664 gp140 trimer (herein referred to as SOSIP). The fact that the SOSIP constructs lack transmembrane and membrane-proximal regions [16] allows finer mapping within gp41 and allows advanced vaccine constructs to be assessed. In a western blot assay, 3F2 did not recognize Bal, gp120, but it did recognize SOSIP and gp41 proteins under non-reducing conditions (Fig. 2D). Upon reduction, SOSIP bands (~ 25 kDa) corresponding to the gp41 protein showed binding. Unlike 2C6, 3F2 did not recognize SOSIP in the ELISA.

Since 2C6 and 3F2 both target gp41 and 2C6 has been shown to have robust ADCC activity against clade B and clade C Gp41 constructs, we next investigated whether 3F2 has ADCC activity. With clade C construct ZA1197 gp41, we saw significant ADCC activity, similar to that of 2C6 and the HIVIG control (Fig. 3).
herein referred to as 8F6 and 5C2) also had ADCC activity. These ID1-targeting Abs also presumably target conformational epitopes of the ID1 region, as they showed variable competition with other ID1-binding Abs (previously published with ID1 Abs 98-6 and 3D6 [2]).

To identify the specific binding site of 3F2, we assessed its binding to three overlapping gp41 peptide libraries of various clades. Each library consisted of 15-mer peptides with 11-amino-acid overlaps, and the results were compared to those obtained with the 2C6 and 2F5 controls. Within each set, mAb 2F5, which recognizes the linear epitope ELDKWA and shows binding to 2-3 overlapping peptides, representing linear epitope targeting, was used as an internal positive control. As shown in a previous publication [4], 2C6 bound specifically and repeatedly to a single peptide within each of the three peptide sets (Fig. 4).
Monoclonal antibody against HIV gp41

In all three peptide sets, 2C6 failed to bind overlapping peptides within the ectodomain of gp41. Despite the lack of binding to clade A gp140 constructs, the best recognition of 3F2 was in the clade A BG505-derived peptide set. Recognition of WGCSGKLICTTNVPW is consistent with ID1 loop binding. However, 3F2 also recognized the peptide ERYLRDQQLLGIWGC, which is also recognized by 2C6.

Despite 3F2 being highly mutated, the antigen binding and peptide binding results are consistent with it being a relatively strain-specific Ab. To confirm the binding seen in peptide ELISA, other peptides were tested. We utilized a set of potential T-cell epitope (PTE) peptides, with numbering representing the internal numbers provided within the original peptide set. We compared binding of 3F2, 2C6, 8F6, and 5C2 against peptides that overlapped the epitopes of 2C6 and the ID1 loop region of gp41. A wide array of these peptides were screened for potential 3F2 binding, with pertinent positives and negatives shown (Fig. 5, Table 1). The pattern of binding mirrored that of the BG505 peptide, with two peptides with minimal overlap (105-VERYLRDQQLLGIWG and 101-CSGKLICTTNVPWNS) showing binding and no binding seen in the intervening peptides. 3F2 showed no binding to peptides that completely overlapped 105 and 101 but had sequence differences (399-VEKYLKDQQLLGIWG and 73-CSGKLICTTNVPWNS; differences underlined). The 101 peptide was also recognized by the ID1-loop-binding Abs 5C2 and 8F6, and intriguingly, at very low levels, 8F6 recognized peptides 105 and 399, but this was variable between assays. Taken together, these data further suggest that 3F2 binds in a conformation-dependent manner and is fairly strain-restricted. In our previous study on 2C6, we created a 25-mer peptide that incorporated the majority of the epitope identified by alanine scanning mutagenesis (Table 1). Consistent with prior data, 2C6 recognizes the 25-mer, and the R579A mutation only partially diminishes 2C6 binding, with other mutations ablating binding in this assay. None of these 25-mer peptides were recognized by 3F2. Notably, these 25-mer peptides had the substitution R588K when compared to the BG505 sequence that is recognized by 3F2.

To identify the binding site of 3F2 on gp41, competition ELISA was performed using various anti-gp41 monoclonal Abs with well-defined epitopes (Fig. 6). 3F2 binding can be competed by 2C6 and F240, but not 2F5. F240 binds to the ID1 loop region, while 2F5 binds to the membrane-proximal immunoglobulin (HIVIG) positive control and similar to that of 2C6 and the ID1-binding Abs discovered in our laboratory. The normalized mean of two replicates with standard deviation is shown.
region (MPER) of gp41. This confirms that 3F2 targets a region in the ID1 loop area. Competition by 3F2 was used as an internal control. This experiment was repeated two times with representative data shown. Despite showing targeting of the same peptide (Figs. 3 and 4), 3F2 did not compete with 2C6. This confirms the previous findings that, although 2C6 can compete with ID1 loop binders, the 2C6 epitope is distinct and does not target the typical ID1 domain epitope [4].

Discussion

Here, we show that the epitope targeted by 3F2 is both conformation-dependent and generally clade-specific, predominantly recognizing clade BaL trimer and clade B JRFL gp140 constructs. Although the binding of 3F2 appears to be relatively specific for clade B proteins, we also observed consistent and quantitatively significant binding to clade A BG505 peptides and show ADCC with a clade C construct. We show that 3F2 binding to trimer was blocked by both 2C6 and F240. This suggests that 3F2 targets an epitope that is near the 2C6 region as well as the ID1 epitope. In the original characterization of these Abs, 2C6 could compete with ID1-binding Abs, but ID1-binding Abs could not compete with 2C6. 3F2 shows a similar pattern to the ID1-binding Abs, suggesting the 3F2 epitope is not centered on 2C6 or does not predominantly target that region, despite the recognition of the same peptide in the BG505 peptide set. This suggests that the Ab 3F2 targets a region between the 2C6 epitope and the ID1 loop area of gp41.

Due to similar variable chain usage, excessive mutation, and cloning from a LTNP subject, we initially hypothesized that 3F2 may also bind the epitope recognized by 2C6. Initial characterization failed to show cross-clade recognition, albeit using a limited dataset. By testing the group M consensus, group B MN, and clade A BG505 peptide sets, we were able to determine that 3F2 binds non-linearly near the epitope of 2C6, as targeting of the same peptide (ERYL-RDQQLLGIGWGC) was shown by 3F2 and 2C6 on clade A BG505. Targeting of this region was confirmed by assessment of 3F2 binding to PTE peptides, as 3F2 and 2C6 bound peptide 105 (CNGKLICTTTPVWN5). Interestingly, 8F6 and 5C2 both more readily recognized peptide 73 (CNGKLICTTAVPWN5), suggesting that these antibodies are less strain-constrained than 3F2. Both 8F6 and 5C2 also utilize VH1-69, with notable very low affinity over background of 8F6 for peptides 105 and 399. The angles of approach and epitope coverage in this region may be more similar with 8F6 and 3F2 than with 2C6 and 3F2. Crystallization studies and finer epitope mapping of these Abs are being pursued to address these subtle differences in targeting of these neighboring regions. Despite 3F2 being highly mutated, the bulk of these data suggest that 3F2 is similar to other loop-binding Abs that appear more strain-specific [17].

Functions other than neutralization, such as ADCC, are thought to be major contributors to the protection seen in the recent successful RV144 vaccine trial [5]. ID1-loop-binding Abs are known to have ADCC activity and generally have limited neutralization breadth [17]. nnAbs targeting structural epitopes in gp41 have been shown to have a significant ADCC function and to limit cell-to-cell spread of infection [8]. nnAbs targeting the ID1 loop epitope of gp41 can even protect macaques against vaginal challenge with SHIV, as was seen with F240 [9] and 7B2 [10]. The Fc portion of Abs, on which ADCC is dependent, is crucial for protection, even in Abs with significant neutralization activity [12].

As our Abs were cloned from an LTNP, it is intriguing to consider a role for specific epitope targeting contributing to this state. Both neutralizing [12, 18, 19] and non-neutralizing [9, 10] Abs have shown some level of protection from infection in challenge models, and there are other clues that these Abs may affect the immunologic state of infected individuals. Cervical IgA responses against gp41 [20] have been confirmed in cohorts of chronically exposed uninfected...
Monoclonal antibody against HIV gp41

Similar responses can be raised by gp41 vaccination and have shown protection of primates against SHIV [22]. Most Abs have no effect on viremia [23], but recent studies have suggested that Abs targeting specific epitopes may affect viremia. The broadly neutralizing Ab PGT121 showed suppression of viremia in an SHIV-infected rhesus model [24]. Suppression of viremia was also demonstrated in humans after infusion with the broadly neutralizing Abs 3BNC117 [25] and 10-1074 [26]. These Ab infusions have also been shown to enhance neutralization [27] and CD8 responses and provide long-lasting stabilization of CD4 levels [28]. The data support a role for immunotherapies as prophylaxis and provides proof of concept that Abs that target specific epitopes can lead to viremic control and may contribute to LTNP.

As the epitope recognized by 2C6 is present on a variety of clades and can support ADCC, further characterization of this epitope is warranted. For clade B studies, 3F2 might be a useful tool to discern binding and reactivity to the 2C6 epitope. Vaccine constructs that were designed to induce 2C6-like Abs are currently in development, and 3F2 Ab could be used to optimize constructs that would focus

**Table 1** Summary of 3F2 binding studies: tabular summary of results of pertinent peptide binding experiments and previous pertinent data

| Protein target | Region | Sequences from the near ID-1 loop | Ab Binding |
|----------------|--------|-----------------------------------|------------|
| **Trimer binding** | HXB2 # | Sequences | 3F2 targeting summary |
| Group M | 575-616 | QLQARVLAVERYLDQQLLG1WGCSGKLICTTC | No peptides |
| Clade B, BaL | 575-616 | QLQARVLAVERYLDQQLLG1WGCSGKLICTTC | Trimer binding |
| Clade B, JRFL | 575-616 | QLQARVLAVERYLDQQLLG1WGCSGKLICTTC | Gp140, diminished |
| Clade B, MN | 575-616 | QLQARVLAVERYLDQQLLG1WGCSGKLICTTC | No peptides |
| Clade A, Bg505 | 575-616 | QLQARVLAVERYLDQQLLG1WGCSGKLICTTC | Two peptides |
| Clade C, ZA119 | 575-616 | QLQARVLAVERYLDQQLLG1WGCSGKLICTTC | ADCC |
| **Peptide binding** | | | Qualitative binding Abs |
| Clade A Bg505 | 584-598 | *ERYLRDQQLLG1WGC* | 3F2/2C6 |
| Clade A Bg505 | 588-602 | RDQQLLG1WGCSGKL | |
| Clade A Bg505 | 592-606 | LGL1WGCSGKLICTT | |
| Clade A Bg505 | 596-610 | *WGLGCSGKLICTTNVPW* | 3F2 |
| PTE 105 | 583-597 | VEYLRDQQLLG1WG | 3F2/2C6/8F6 |
| PTE 399 | 583-597 | VELYLRDQQLLG1WG | 2C6/8F6 |
| PTE 10 | 589-603 | DQQLLG1WGCSGKL | |
| PTE 183 | 589-603 | DQQLLG1WGCSGKL | |
| PTE 342 | 593-607 | LGI1WGCSGKLICTTN | |
| PTE 73 | 598-612 | CG1KLICTTNVPWNS | 3C2/8F6 |
| PTE 101 | 598-612 | CG1KLICTTNVPWNS | 3F2/5C2/8F6 |
| 2C6 25-mer (from Sojar, et al, 2019) | 575-599 | QLQARVLAVERYLDQQLLG1WGCS (native) | |
| 2C6 25-mer (from Sojar, et al, 2019) | 575-599 | QLQARVLAVERYLDQQLLG1WGCS (R579A) | 2C6 |
| 2C6 (diminished) | 575-599 | QLQARVLAVERYLDQQLLG1WGCS (R579A) | |
| **Alanine Scanning data** | | | |
| Sojar et al, 2019 | R | L | IW | 2C6 |
| Hicar et al, Plos One, 2016 | W | C | G | L | 5C2/8F6 |

Bolded amino acids are those that vary from BG505 peptides recognized by 3F2 (*) or consensus in regions outside these peptides. Decreased binding of the Ab is indicated by a grey font.

**Fig. 6** Non-reciprocal competition distinguishes 2C6 from 3F2. Unlabeled monoclonal Abs diluted from 1000 ng/mL to 0 ng/mL were used in a competitive binding assay with 200 ng of biotinylated 3F2 (A) or 200 ng of biotinylated 2C6 (B) per mL. The data are representative of two experiments.

Individuals [21]. Similar responses can be raised by gp41 vaccination and have shown protection of primates against mucosal challenge with SHIV [22]. Most Abs have no effect on viremia [23], but recent studies have suggested that Abs targeting specific epitopes may affect viremia. The broadly neutralizing Ab PGT121 showed suppression of viremia in an SHIV-infected rhesus model [24]. Suppression of viremia was also demonstrated in humans after infusion with the broadly neutralizing Abs 3BNC117 [25] and 10-1074 [26]. These Ab infusions have also been shown to enhance neutralization [27] and CD8 responses and provide long-lasting stabilization of CD4 levels [28]. The data support a role for immunotherapies as prophylaxis and provides proof of concept that Abs that target specific epitopes can lead to viremic control and may contribute to LTNP.

As the epitope recognized by 2C6 is present on a variety of clades and can support ADCC, further characterization of this epitope is warranted. For clade B studies, 3F2 might be a useful tool to discern binding and reactivity to the 2C6 epitope. Vaccine constructs that were designed to induce 2C6-like Abs are currently in development, and 3F2 Ab could be used to optimize constructs that would focus
responses on the 2C6 epitope and away from more strain-specific structures recognized by Abs such as 3F2.

Acknowledgements We thank Dr. J.P. Moore & Klasse P.J. for providing BG505 SOSIP trimer. We thank Dr. J. Bloom for providing influenza-virus-specific monoclonal Ab F16V3. The following reagents were obtained through the AIDS Research and Reference Reagent Program, Division of AIDS, NIAID, NIH; peptide sets group M, clade A BG5050, clade B MN envelope; and potential T-cell epitope (PTE) peptide array of HIV-1 envelope region contributed by DAIDS/NIAID; recombinant gp140 proteins UG 37(A), JRFL (B), CN54 (C), UG21 (D), and Bro29 (F); recombinant Gp41 protein HIV-1 MN Gp41; and monoclonal Abs 2G12 and 2F5 from Dr. Hermann Katinger and F240 from Dr. Marshall Posner and Dr. Lisa Cavacini.

Author contributions: All authors contributed to the study conception and design. Material preparation, data collection, and analysis were performed by Devin DeCotes, Sarah Baron, Jonathon Hoffman, Meghan Garrett, and Hakimuddin Sojar. The first draft of the manuscript and design. Material preparation, data collection, and analysis were performed by Devin DeCotes, Sarah Baron, Jonathon Hoffman, Meghan Garrett, and Hakimuddin Sojar. The first draft of the manuscript was written by Devine DeCotes and Mark Hicar, and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

Funding This work was supported by NIH R01 AI 125119-01; “The role of non-broadly neutralizing antibodies targeting gp41 structural epitopes in long term nonprogression of HIV infection,” Hicar, Primary Investigator.

References

1. McCoy LE, Burton DR (2017) Identification and specificity of broadly neutralizing antibodies against HIV. Immunol Rev. 275:11–20. https://doi.org/10.1111/imr.12484
2. Hicar MD, Chen X, Sulli C, Barnes T, Goodman J, Sojar H, Briney B, Willis J, Chukwuma BU, Kalams SA, Doranz BJ, Spearman P, Crowe JE Jr (2016) Human antibodies that recognize novel immunodominant quaternary epitopes on the HIV-1 env protein. PLoS One. 11:e0158861. https://doi.org/10.1371/journal.pone.0158861
3. Hicar MD, Chen X, Kalams SA, Sojar H, Landucci G, Forthal DN, Spearman P, Crowe JE Jr (2016) Low frequency of broadly neutralizing HIV antibodies during chronic infection even in quaternary epitope targeting antibodies containing large numbers of somatic mutations, Mol Immunol. 70:94–103. https://doi.org/10.1016/j.molimm.2015.12.002
4. Sojar H, Baron S, Sullivan JT, Garrett M, Van Haaren MM, Hoffman J, Overbaugh J, Doranz BJ, Hicar MD (2019) Monoclonal antibody 2C6 targets a cross-clade conformational epitope in gp41 with highly active antibody-dependent cell cytotoxicity. J Virol. https://doi.org/10.1128/JVI.00772-19
5. Haynes BF, Gilbert PB, Mcelrath MJ, Zolla-Pazner S, Tomaras GD, Alam SM, Evans DT, Montefiori DC, Karnasuta C, Suthenth R, Liao RX, Devico AL, Lewis GK, Williams C, Pinter A, Fong Y, Janes H, Decamp A, Huang Y, Rao M, Billings E, Karasavvas N, Robb ML, Ngauy V, De Souza MS, Paris R, Ferrari G, Bailer RT, Soderberg KA, Andrews C, Berman PW, Frahm N, De Rosa SC, Alpert MD, Yates NL, Shen X, Koup RA, Pittsuttithum P, Kaewkungwal J, Niyayahpan S, Reker-Ngarm S, Michael NL, Kim JH (2012) Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med. 366:1275–86. https://doi.org/10.1056/NEJMoa1113425
6. Acharya P, Tolbert WD, Gohain N, Wu X, Yu L, Liu T, Huang W, Huang CC, Kwon YD, Louder RK, Luongo TS, McEllan JS, Pancera M, Yang Y, Zhang B, Flinko R, Foulke JS Jr, Sajadi MM, Kamin-Lewis R, Robinson JE, Martin L, Kwong PD, Guan Y, Devico AL, Lewis GK, Pazger M (2014) Structural definition of an antibody-dependent cellular cytocytotoxic response implicated in reduced risk for HIV-1 infection. J Virol. 88:12895–906. https://doi.org/10.1128/JVI.02194-14
7. Schmaljohn AL (2013) Protective antiviral antibodies that lack neutralizing activity: precedents and evolution of concepts. Curr HIV Res 11:345–353
8. Bonsignori M, Pollara J, Moody MA, Alpert MD, Chen X, Wang KK, Gilbert PB, Huang Y, Gurley TC, Kozink DM, Marshall DJ, Whitesides JF, Tsao CY, Kauwkgungwal J, Niyayahpan S, Pittsuttithum P, Rekers-Ngarm S, Kim JH, Michael NL, Tomaras GD, Montefiori DC, Lewis GK, Devico A, Evans DT, Ferrari G, Liao HX, Haynes BF (2012) Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family. J Virol. 86:11521–32. https://doi.org/10.1128/JVI.01023-12
9. Burton DR, Hessel AJ, Keel BF, Klasse PJ, Ketens TA, Moldt B, Dunlop DC, Poignard P, Doyle LA, Cavacini L, Veazey RS, Moore JP (2011) Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody. Proc Natl Acad Sci USA. 108:11181–6. https://doi.org/10.1073/pnas.1103012108
10. Santra S, Tomaras GD, Warrier R, Nicely NL, Liao HX, Pollara J, Liu P, Alam SM, Zhang R, Cocklin SL, Shen X, Duffy R, Xia SM, Schutte RJ, Pembie IV CW, Dennison SM, Li H, Chao A, Vidnovic E, Andrews A, Klein K, Kumar A, Robinson J, Landucci G, Forthal DN, Montefiori DC, Kauwkgungwal J, Niyayahpan S, Pittsuttithum P, Rekers-Ngarm S, Robb ML, Michael NL, Kim JH, Soderberg KA, Giorgi EE, Blair L, Korber BT, Moog C, Shattock RJ, Letvin NL, Schmitz JE, Moody MA, Gao F, Ferrari G, Shaw GM, Haynes BF (2015) Human non-neutralizing HIV-1 envelope monoclonal antibodies limit the number of founder viruses during SHIV mucosal infection in rhesus macaques. PLoS Pathog. 11:e1005042. https://doi.org/10.1371/journal.ppat.1005042
11. Moog C, Dereeude-Bosquet N, Teillaud JE, Biedma ME, Holf V, Van Ham G, Heyndricks L, Van Dorsselaer A, Katinger D, Vcelar B, Zolla-Pazner S, Mangeot I, Kelly C, Shattock RJ, LeGrand R (2014) Protective effect of vaginal application of neutralizing and nonneutralizing inhibitory antibodies against vaginal SHIV challenge in macaques. Mucosal Immunol. 7:46–56. https://doi.org/10.1038/mi.2013.23
12. Hessel AJ, Hangartner L, Hunter M, Havenith CE, Beurskens FJ, Bakker JS, Lanigan CM, Landucci G, Forthal DN, Parren PW, Marx PA, Burton DR (2007) Fc receptor but not complement binding is important in antibody protection against HIV. Nature. 449:101–4. https://doi.org/10.1038/nature06106
13. De Taeye SW, Ozorowski G (2015) Immunogenicity of stabilized HIV-1 envelope trimers with reduced exposure of non-neutralizing epitopes. Cell. 163:1702–15. https://doi.org/10.1016/j.cell.2015.11.056
14. Torrents De La Pena A, De Taeye SW, Slipen K, Labranche CC, Burger JA, Schermer EE, Montefiori DC, Moore JP, Klasse PJ, Sanders RW (2018) Immunogenicity in rabbits of HIV-1 SOSIP trimers from clades A, B, and C, given individually, sequentially, or in combination. J Virol. https://doi.org/10.1128/JVI.01957-17
15. Brochet X, Lefranç MP, Giudicelli V (2008) IMGT/V-QUEST: the highly customized and integrated system for IG and TR
standardized V-J and V-D-J sequence analysis. Nucl Acids Res 36:W503–W508
16. Sanders RW, Derking R, Cupo A, Julien JP, Yasmeen A, De Val N, Kim HJ, Blattner C, De La Pena AT, Korzun J, Golabek M, De Los Reyes K, Ketas TJ, Van Gils MJ, King CR, Wilson IA, Ward AB, Klasse PJ, Moore JP (2013) A next-generation cleaved, soluble HIV-1 Env Trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies. PLoS Pathog 9:e1003618. https://doi.org/10.1371/journal.ppat.1003618
17. Bruel T, Guivel-Benhassine F, Lorin V, Lortat-Jacob H, Baleux F, Bourdic K, Noel N, Lambotte O, Mouquet H, Schwartz O (2017) Lack of ADCC breadth of human nonneutralizing anti-HIV-1 antibodies. J Virol. https://doi.org/10.1128/JVI.02440-16
18. Parren PW, Marx PA, Hessel A, Luckay A, Harousse J, Cheng-Mayer C, Moore JP, Burton DR (2001) Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J Virol 75:8340–8347
19. Parren PW, Dittrich HJ, Gulizia RJ, Binley JM, Barbos CF 3rd, Burton DR, Moser DE (1995) Protection against HIV-1 infection in hu-PBL-SCID mice by passive immunization with a neutralizing human monoclonal antibody against the gp120 CD4-binding site. AIDS 9:F1-6
20. Tudor D, Derrien M, Diomede L, Drillet AS, Houime M, Moog C, Reyes JM, Lopalco L, Boschel M (2009) HIV-1 gp41-specific monoclonal mucosal IgAs derived from highly exposed but IgG-seronegative individuals block HIV-1 epithelial transcytosis and neutralize CD4 (+) cell infection: an IgA gene and functional analysis. Mucosal Immunol. 2:412–26. https://doi.org/10.1038/mi.2009.89
21. Miyazawa M, Lopalco L, Mazzotta F, Lo Caputo S, Vias F, Clerici M, Group ESNS (2009) The “immunologic advantage” of HIV-exposed seronegative individuals. AIDS 23:161–75. https://doi.org/10.1097/QAD.0b013e3283196a80
22. Bomse M, Tudor D, Drillet AS, Alfsen A, Ganor Y, Roger MG, Mouz N, Amacker M, Chalifour A, Diomede L, Devillier G, Cong Z, Wei Q, Gao H, Qin C, Yang GB, Zurbriggen R, Lopalco L, Fleury S (2011) Immunization with HIV-1 gp41 subunit viruses induces mucosal antibodies protecting nonhuman primates against vaginal SHIV challenges. Immunity. 34:269–80. https://doi.org/10.1016/j.immuni.2011.01.015
23. Gaardbo JC, Hartling HJ, Gerstoft J, Nielsen SD (2012) Thirty years with HIV infection-nonprogression is still puzzling: lessons to be learned from controllers and long-term nonprogressors. AIDS Res Treat. 2012:161584. https://doi.org/10.1155/2012/161584
24. Barouch DH, Whitney JB, Moldt B, Klein F, Oliveira TY, Liu J, Stephenson KE, Chang HW, Shekar K, Gupta S, Nkoloa JP, Seaman MS, Smith KM, Boudoumi EN, Cabil C, Smith JY, Blackmore S, Sanissetty S, Perry JR, Beck M, Lewis MG, Rinaldi W, Chakraborty AK, Poignard P, Nussenzein WC, Burton DR (2013) Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys. Nature. 503:224–8. https://doi.org/10.1038/nature12744
25. Caskey M, Klein F, Lorenzi JC, Seaman MS, West AP Jr, Buckley N, Kremer G, Nogueira L, Braunenschweig M, Scheid JP, Hortwitz JA, Shmilovich I, Ben-Avraham S, Witmer-Pal M, Plattan M, Lehnmann C, Burke LA, Hawthorne T, Gorelick R, Walker BD, Keler T, Gulic RM, Fatenheuer G, Schlesinger SJ, Nussenzein WC (2015) Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. Nature. 522:487–91. https://doi.org/10.1038/nature14411
26. Caskey M, Schoofs T, Gruell H, Seltter A, Karagounis T, Kreider EF, Murrell B, Pfeifer N, Nogueira L, Oliveira TY, Learn GH, Cohen YZ, Lehmnan C, Gillor D, Shmilovich I, Unson-O’Brien C, Weiland D, Robles A, Kummerle T, Wyen C, Levin R, Witmer-Pal M, Eren K, Ignacio C, Kiss S, West AP Jr, Mouquet H, Zingman BS, Gulic RM, Keler T, Bjorkman PJ, Seaman MS, Hahn BH, Fatenheuer G, Schlesinger SJ, Nussenzein WC, Klein F (2017) Antibody 10–1074 suppresses viremia in HIV-1-infected individuals. Nat Med. 23:185–191. https://doi.org/10.1038/nm.4268
27. Schoofs T, Klein F, Braunenschweig M, Kreider EF, Feldmann A, Nogueira L, Oliveira T, Lorenzi JC, Parrish EH, Learn GH, West AP Jr, Bjorkman PJ, Schlesinger SJ, Seaman MS, Czartoski J, Mcelrath MJ, Pfeifer N, Hahn BH, Caskey M, Nussenzein WC (2016) HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1. Science. 352:997–1001. https://doi.org/10.1126/science.aaf0972
28. Nishimura Y, Gautam R, Chun TW, Sudjapour R, Foulds KE, Shingai M, Klein F, Gazumyan A, Golijanin J, Donaldson M, Donau OK, Plisheka RJ, Buckler-White A, Seaman MS, Lifson JD, Koup RA, Fauzi AS, Nussenzein WC, Martin MA (2017) Early antibody therapy can induce long-lasting immunity to SHIV. Nature. 543:559–563. https://doi.org/10.1038/nature21435
Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.